Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of trametinib in treating patients
with cancer that has spread to other places in the body and usually cannot be cured or
controlled with treatment (advanced) with or without liver (hepatic) dysfunction. Trametinib
may stop the growth of tumor cells by blocking proteins needed for cell growth. When these
proteins are blocked, the growth of cancer cells may be stopped and the cancer cells will
then die. Hepatic dysfunction is frequently found in patients with advanced cancer and
usually prevents patients from receiving standard treatments or from participating in
clinical trials. Patients may also need dose adjustments or absorb drugs differently.
Trametinib may be a better treatment for patients with advanced cancers and hepatic
dysfunction.